- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07940400
Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer (ICEBERG-PC)
ICEBERG-PC: Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer: A Single-Site AmbidirectionalObservational Outcomes Cohort
Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment, and functional outcomes can be analyzed together. The historical component will provide a background population for understanding treatment patterns and outcomes when Decipher® and/or PSMA PET were not obtained. It will not be treated as a formal randomized or concurrent comparator arm. This study is designed to observe that real-world clinical process without assigning testing, imaging, or treatment.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Sachin Vyas, MS,PhD
- Telefonnummer: 336-713-4098
- E-post: Sachin.vyas@advocatehealth.org
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
Hovedetterforsker:
- Thomas Polascik, MD
-
Ta kontakt med:
- Sachin Vyas, MS, PhD
- Telefonnummer: 336-713-4098
- E-post: Sachin.Vyas@Advocatehealth.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Diagnosis of prostate cancer
Beskrivelse
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of prostate cancer documented in the institutional medical record. Prostate adenocarcinoma will constitute the principal analytic population, while other prostate cancer histology's may be retained for descriptive background analyses when clinically relevant.
- Evaluation, diagnosis, treatment, or follow-up within or beyond Advocate Health Wake Forest Baptist / Wake Forest University School of Medicine and availability of sufficient clinical information for at least one study objective.
- For the prospective component, first ascertainment after protocol activation will be conducted through routine clinical records or institutional clinical data systems.
- For the historical background component, available institutional records predating protocol activation will be used to characterize prostate cancer presentation, management, and outcomes
Exclusion Criteria:
- Insufficient clinical information to establish the relevant diagnosis, treatment, or outcome for a proposed analysis.
- Records that cannot be used under applicable institutional privacy, data-governance, or IRB requirements.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Patients been diagnosed with the prostate cancer
To determine how clinically obtained tumor genomic and transcriptomic features, phenotype, real-world treatment selection, and longitudinal oncologic outcomes |
This study involves no study specific intervention |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prostate-Specific Membrane Antigen (PSMA) PET disease extent
Tidsramme: up to 5 years
|
Prostate-Specific Membrane Antigen (PSMA) PET disease extent among patients with clinically obtained Decipher® and PSMA PET, classified as localized versus nonlocalized disease using available molecular-imaging staging data. |
up to 5 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Thomas Polascik, MD, Wake Forest University Health Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB00157301
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .